利拉鲁肽联合瑞格列奈对2型糖尿病患者血糖和胰岛素抵抗的影响

Effects of Lilarutide Combined with Repaglinide on Blood Glucose and Insulin Resistance in Patients with Type 2 Diabetes Mellitus

目的评估利拉鲁肽联合瑞格列奈对2型糖尿病患者血糖和胰岛素抵抗的影响。方法选取2016年5月—2019年5月收治的2型糖尿病患者60例为研究对象,按是否联合应用瑞格列奈分为研究组和对照组,每组30例。对照组给予利拉鲁肽治疗,研究组给予利拉鲁肽联合瑞格列奈治疗。比较2组治疗前后的空腹血糖(FPG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)、肿瘤坏死因子-α(TNF-α)、白介素-1β(IL-1β)、超敏C反应蛋白(hs-CRP)、胰岛素抵抗指数(HOMA-IR)以及β-细胞功能指数(HOMA-β)水平,并观察不良反应发生情况。结果治疗后,2组FPG、2 hPG、HbA1c、IL-1β、TNF-α、hs-CRP水平均明显低于治疗前,且研究组均明显低于对照组(P<0.05)。治疗后,研究组的HOMA-β以及HOMA-IR水平较治疗前明显改善,且HOMA-β水平明显高于对照组,HOMA-IR水平明显低于对照组(P<0.05)。2组不良反应总发生率比较差异无统计学意义(P>0.05)。结论利拉鲁肽联合瑞格列奈治疗2型糖尿病,可以有效控制患者血糖,降低胰岛素抵抗情况,改善机体炎性反应状态,具有较高的安全性。

Objective To evaluate the effects of Lilarutide combined with Repaglinide on blood glucose and insulin resistance in patients with type 2 diabetes mellitus(T2DM).Methods A total of 60 patients with T2DM who were treated from May 2016 to May 2019 were selected as the research subjects.They were divided into research group(n=30)and control group(n=30)according to application of combination therapy with Rigaglinide.The control group was treated with Liraglutide,while the research group was treated with Liraglutide combined with Regglinide.The fasting blood glucose(FPG),2 h postprandial blood glucose(2 hPG),glycosylated hemoglobin(HbA1c),tumor necrosis factor-α(TNF-α),interleukin-1β(IL-1β),high sensitive C-reactive protein(hs-CRP),insulin resistance index(HOMA-IR)andβ-cell function index(HOMA-β)were compared before and after treatment in the two groups,and the adverse reactions were observed.Results After treatment,the levels of FPG,2 hPG,HbA1c,IL-1β,TNF-αand hs-CRP in the two groups were significantly lower than those before treatment,and those in the research group were significantly lower than those in the control group(P<0.05).After treatment,the level of HOMA-βand HOMA-IR in the research group was significantly improved compared with that before treatment,and the level of HOMA-βwas significantly higher than that in the control group,while the level of HOMA-IR was significantly lower than that in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Lilarutide combined with Repaglinide in the treatment of T2DM can effectively control the patient's blood glucose,reduce insulin resistance,and improve the inflammatory response of the body,with higher safety.